Advertisement


Sara A. Hurvitz, MD, on HR-Positive, HER2-Negative Breast Cancer: Results of the neoMONARCH Trial

2016 San Antonio Breast Cancer Symposium

Advertisement

Sara A. Hurvitz, MD, of the UCLA Jonsson Comprehensive Cancer Center, discusses findings on the biological effects of abemaciclib in a neoadjuvant study for postmenopausal patients (Abstract S4-06).



Related Videos

Breast Cancer

Rowan T. Chlebowski, MD, PhD, on Diet and Breast Cancer: Trial Results

Rowan T. Chlebowski, MD, PhD, of the David Geffen School of Medicine at UCLA, discusses findings from the Women’s Health Initiative Dietary Modification study on low-fat diet and brea...

Breast Cancer
Symptom Management

Anne Hudson Blaes, MD, on Aromatase Inhibitors and Cardiovascular Disease

Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).

Breast Cancer

Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial

Aleix Prat, MD, PhD, of the University of Barcelona, discusses study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 block...

Breast Cancer

Harold J. Burstein, MD, PhD, on Adjuvant Endocrine Therapy: Expert Perspective

Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data ...

Breast Cancer

Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial (Spanish Language Version)

Aleix Prat, MD, PhD, of the University of Barcelona, discusses in Spanish study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual...

Advertisement

Advertisement



Advertisement